Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232835 | 1.00 | HTR2C (0.45) | HTR2CJAK3LMNATSHRSLC6A2 | |
| SCHEMBL4431279 | 0.91 | HTR2C (0.55) | HTR2CLMNATSHRSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5729720 | 0.90 | HTR2C (0.56) | HTR2CLMNATSHRSLC6A2SLC6A4 | |
| SCHEMBL31283988 | 0.86 | PDK2 (0.40) | — | |
| SCHEMBL25063283 | 0.82 | LMNA (0.53) | LMNATSHR | |
| SCHEMBL30776200 | 0.81 | JAK3 (0.49) | HTR2CJAK3SLC6A2SLC6A4 | |
| SCHEMBL1663055 | 0.81 | JAK3 (0.49) | HTR2CJAK3SLC6A2SLC6A4 | |
| SCHEMBL4213803 | 0.81 | JAK3 (0.49) | HTR2CJAK3SLC6A2SLC6A4 | |
| Tert-Butyl Formate SCHEMBL27815351 | 0.80 | HTR2C (0.45) | HTR2CSLC6A2SLC6A4 | |
| SCHEMBL14869717 | 0.80 | PARP1 (0.54) | JAK3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| CN-119176772-A | Compound with Mrgpr X receptor inhibition effect and application thereof | 博济医药科技股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | HTR2C 601/4885JAK3 1555/4885LMNA 4656/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | HTR2C 601/4885JAK3 1555/4885LMNA 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.